The stock of Theralase Technologies Inc. (CVE:TLT) hit a new 52-week low and has $0.23 target or 13.00% below today’s $0.26 share price. The 5 months bearish chart indicates high risk for the $28.56 million company. The 1-year low was reported on Nov, 8 by Barchart.com. If the $0.23 price target is reached, the company will be worth $3.71M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 2.04M shares traded hands or 345.71% up from the average. Theralase Technologies Inc. (CVE:TLT) has risen 6.00% since October 9, 2016 and is uptrending. It has outperformed by 4.04% the S&P500.
More news for Theralase Technologies Inc. (CVE:TLT) were recently published by: Midasletter.com, which released: “Theralase Technologies Inc: A Cure for Cancer?” on February 24, 2014. Business.Financialpost.com‘s article titled: “Podcast: Theralase Technologies CEO on using light for pain and cancer treatment” and published on June 15, 2016 is yet another important article.
Theralase Technologies Inc. is a biotech firm focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds to destroy cancer. The company has a market cap of $28.56 million. The Firm operates through two divisions: Therapeutic Laser Technology (TLT) division and Photo Dynamic Therapy (PDT) division. It currently has negative earnings. The TLT division designs, develops, makes and markets super-pulsed laser technology indicated for the healing of chronic knee pain.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.